Biocept, Inc. is an early stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor nucleic acid, including circulating tumor deoxyribonucleic acid (ctDNA) and circulating tumor ribonucleic acid (ctRNA), assays using a standard blood sample or liquid biopsy. Its blood and cerebrospinal fluid (CSF) assays are intended to provide information to aid healthcare providers by identifying tumor cells associated with progression or metastasis and identifying specific oncogenic alterations that may qualify a subset of cancer patients for targeted therapy. The Company's Target-Selector CTC and molecular platforms provide both biomarker detection as well as monitoring capabilities and require only a patient blood sample or CSF sample to inform treatment decisions. It also offers sensitive polymerase chain reaction (PCR) based assay through Aegea Biotechnologies, Inc. (Aegea) for detecting the COVID-19 virus.